

# Iptacopan in Patients With ANCA Associated Vasculitis

Last Update: Mar 27, 2025

A Randomized, Controlled Study to Evaluate LNP023 (Iptacopan) in Patients With Active ANCA-associated Vasculitis

ClinicalTrials.gov Identifier:

[NCT06388941](#)

Novartis Reference Number:CLNP023R12201

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

## Study Description

The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study participants with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), when used in combination with rituximab (RTX) induction. The trial will also assess the impact of iptacopan on disease relapses, evolution of renal function and proteinuria, GC side effects, patients' immune status, and QoL. This is a randomized, controlled study to evaluate the efficacy and safety of iptacopan in combination with RTX induction therapy for the treatment of newly diagnosed or relapsed patients with active GPA or MPA.

Condition

Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis

Phase

Phase2

Overall Status

Recruiting

Number of Participants

78

Start Date

Aug 05, 2024

Completion Date

Oct 05, 2027

Gender

All

Age(s)

18 Years - 100 Years (Adult, Older Adult)

## Interventions

Drug

## **Iptacopan**

LNP023 administered orally

Drug

## **Placebo**

Matching placebo administered orally

Drug

## **Rituximab**

Standard of care

## **Eligibility Criteria**

Inclusion Criteria:

- \* Newly diagnosed or relapsed GPA and MPA (according to the 2022 ACR/EULAR classification criteria for GPA and MPA) requiring treatment with RTX and GC as per investigator's judgement.
- \* BVAS assessment with  $\geq 1$  major item, or  $\geq 3$  minor items, or  $\geq 2$  renal items at Screening.
- \* Positive antibody test for anti-proteinase 3 (PR3) or anti-myeloperoxidase (MPO) antibodies at Screening or with history of documented evidence of a positive antibody test.

Exclusion Criteria:

- \* Other systemic disease which constitutes the primary illness, including but not limited to: eosinophilic granulomatosis with polyangiitis (EGPA), moderate to severe systemic lupus erythematosus, IgA vasculitis (Purpura Schönlein-Henoch), rheumatoid vasculitis, Sjögren's syndrome, anti-glomerular basement membrane (GBM) disease, cryoglobulinemic vasculitis, autoimmune hemolytic anemia, autoimmune lymphoproliferative syndrome or mixed connective tissue disease.
- \* Alveolar hemorrhage requiring invasive pulmonary ventilation support at Screening.
- \* Severe kidney disease defined as estimated glomerular filtration rate (eGFR)  $< 15$  mL/minute/1.73m<sup>2</sup>, or kidney failure defined as receiving renal replacement therapy such as hemo(dia)filtration, hemo-/peritoneal dialysis, or having received a kidney transplant.
- \* Received plasma exchange/-pheresis within 12 weeks prior to Screening.

## **Argentina**

### **Novartis Investigative Site**

Recruiting

Caba,Buenos Aires,C1180aax,Argentina

### **Novartis Investigative Site**

Recruiting

Caba,Buenos Aires,C1181ach,Argentina

**Novartis Investigative Site**

Recruiting

La Plata,Buenos Aires,B1900awt,Argentina

**Australia**

**Novartis Investigative Site**

Recruiting

Westmead,New South Wales,2145,Australia

**Novartis Investigative Site**

Recruiting

Adelaide,South Australia,5000,Australia

**Novartis Investigative Site**

Recruiting

Clayton,Victoria,3168,Australia

**Novartis Investigative Site**

Recruiting

Concord,New South Wales,2139,Australia

**Austria**

**Novartis Investigative Site**

Recruiting

Graz,8036,Austria

**Novartis Investigative Site**

Recruiting

Wien,1090,Austria

**Canada**

**Novartis Investigative Site**

Recruiting

Fleurimont,Quebec,J1h 5n4,Canada

**Novartis Investigative Site**

Recruiting

Montreal,Quebec,H2x 1r9,Canada

**Novartis Investigative Site**

Recruiting

Montreal,Quebec,H4j 1c5,Canada

**Novartis Investigative Site**

Recruiting

Quebec,G1r 2j6,Canada

**Novartis Investigative Site**

Recruiting

London,Ontario,N6a 5w9,Canada

**China**

**Novartis Investigative Site**

Recruiting

Shijiazhuang,Hebei,050000,China

**Novartis Investigative Site**

Recruiting

Zhengzhou,Henan,450052,China

**Novartis Investigative Site**

Recruiting

Shanghai,Shanghai,200032,China

**Czechia**

**Novartis Investigative Site**

Recruiting

Praha,12808,Czechia

## **Denmark**

### **Novartis Investigative Site**

Recruiting

Aarhus N,8200,Denmark

### **Novartis Investigative Site**

Recruiting

Herlev,Dk-2730,Denmark

### **Novartis Investigative Site**

Recruiting

Kobenhavn O,Dk-2100,Denmark

## **France**

### **Novartis Investigative Site**

Recruiting

Paris,75014,France

### **Novartis Investigative Site**

Recruiting

Toulouse 4,31054,France

### **Novartis Investigative Site**

Recruiting

Angers Cedex 9,49933,France

### **Novartis Investigative Site**

Recruiting

Brest,29200,France

### **Novartis Investigative Site**

Recruiting

Dijon,21034,France

### **Novartis Investigative Site**

Recruiting

Marseille,13385,France

## **Germany**

### **Novartis Investigative Site**

Recruiting

Berlin,13353,Germany

### **Novartis Investigative Site**

Recruiting

Muenchen,81377,Germany

### **Novartis Investigative Site**

Recruiting

Kirchheim Unter Teck,Baden-Wuerttemberg,73230,Germany

## **Hungary**

### **Novartis Investigative Site**

Recruiting

Budapest,H-1083,Hungary

### **Novartis Investigative Site**

Recruiting

Debrecen,4032,Hungary

### **Novartis Investigative Site**

Recruiting

Szeged,6720,Hungary

## **Netherlands**

### **Novartis Investigative Site**

Recruiting

Groningen,9713 gz,Netherlands

## **Spain**

### **Novartis Investigative Site**

**Novartis Investigative Site**

Recruiting

Pamplona,Navarra,31008,Spain

**Novartis Investigative Site**

Recruiting

Madrid,28046,Spain

**Novartis Investigative Site**

Recruiting

Plasencia,Extremadura,10600,Spain

**Turkey**

**Novartis Investigative Site**

Recruiting

Ankara,06230,Turkey

**Novartis Investigative Site**

Recruiting

Ankara,06500,Turkey

**Novartis Investigative Site**

Recruiting

Pendik Istanbul,34899,Turkey

**United States**

**Mayo Clinic Rochester**

Recruiting

Rochester,Minnesota,55905,United States

Jodi Mahon

Phone: [507-284-2467](tel:507-284-2467)

Email: [mahon.jodi@mayo.edu](mailto:mahon.jodi@mayo.edu)

Ulrich Specks

**Northwell Health**

Recruiting

New York, New York, 10028, United States

Phone: [516-708-2550](tel:516-708-2550)

Lara El Khoury

### **Arizona Arthritis and Rheumatology Research PLLC**

Recruiting

Mesa, Arizona, 85202, United States

Areena Swarup

Mandee Lochridge

Email: [Mandee.Lochridge@azarthritis.com](mailto:Mandee.Lochridge@azarthritis.com)

## **Worldwide Contacts**

If the location of your choosing does not feature any contact detail, please reach out using the information below.

### **Novartis Pharmaceuticals**

Phone: [+41613241111](tel:+41613241111)

Email:

### **Novartis Pharmaceuticals**

Phone: [1-888-669-6682](tel:1-888-669-6682)

Email: [novartis.email@novartis.com](mailto:novartis.email@novartis.com)

---

**Source URL:** <https://prod1.novartis.com/clinicaltrials/study/nct06388941>

### **List of links present in page**

1. <https://clinicaltrials.gov/ct2/show/NCT06388941>
2. [#trial-eligibility](#)
3. <tel:507-284-2467>
4. <mailto:mahon.jodi@mayo.edu>
5. <tel:516-708-2550>
6. <mailto:Mandee.Lochridge@azarthritis.com>
7. <tel:+41613241111>
8. <mailto:>
9. <tel:1-888-669-6682>
10. <mailto:novartis.email@novartis.com>